These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 15837257)

  • 1. Should we consider aldosterone as the primary screening target for preventing cardiovascular events?
    Francis GS; Tang WH
    J Am Coll Cardiol; 2005 Apr; 45(8):1249-50. PubMed ID: 15837257
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular outcomes in patients with primary aldosteronism after treatment.
    Catena C; Colussi G; Nadalini E; Chiuch A; Baroselli S; Lapenna R; Sechi LA
    Arch Intern Med; 2008 Jan; 168(1):80-5. PubMed ID: 18195199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aldosterone blockade in essential hypertension].
    Venco A; Grandi AM
    Ital Heart J; 2005 May; 6 Suppl 1():34S-42S. PubMed ID: 15945298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas.
    Karagiannis A; Tziomalos K; Kakafika AI; Athyros VG; Harsoulis F; Mikhailidis DP
    Endocr Relat Cancer; 2008 Sep; 15(3):693-700. PubMed ID: 18586836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone receptor antagonism in heart failure.
    Jennings DL; Kalus JS; O'Dell KM
    Pharmacotherapy; 2005 Aug; 25(8):1126-33. PubMed ID: 16207104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension.
    Sharabi Y; Adler E; Shamis A; Nussinovitch N; Markovitz A; Grossman E
    Am J Hypertens; 2006 Jul; 19(7):750-5. PubMed ID: 16814132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone and cardiovascular disease.
    Gaddam KK; Pimenta E; Husain S; Calhoun DA
    Curr Probl Cardiol; 2009 Feb; 34(2):51-84. PubMed ID: 19135616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone and Cardiovascular Disease. Foreword.
    Rahimtoola SH
    Curr Probl Cardiol; 2009 Feb; 34(2):49. PubMed ID: 19135615
    [No Abstract]   [Full Text] [Related]  

  • 10. Aldosterone and cardiovascular disease: smoke and fire.
    Calhoun DA
    Circulation; 2006 Dec; 114(24):2572-4. PubMed ID: 17159070
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?
    Coca SG; Perazella MA
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):497-512. PubMed ID: 15889977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A symposium: International update--the important role of aldosterone and aldosterone antagonism in cardiovascular medicine. Based on symposia held in Brussels, Belgium and Newport Beach, California.
    Am J Cardiol; 1990 Jun; 65(23):1K-57K. PubMed ID: 2353664
    [No Abstract]   [Full Text] [Related]  

  • 13. Importance of controlling blood pressure.
    MacGregor GA; He FJ
    Climacteric; 2005 Oct; 8 Suppl 3():13-8. PubMed ID: 16203651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypertension in patients with diabetes].
    Poulsen PL; Hansen KW; Gaede PH; Rossing P
    Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone synthase inhibitors: pharmacological and clinical aspects.
    Jansen PM; van den Meiracker AH; Jan Danser AH
    Curr Opin Investig Drugs; 2009 Apr; 10(4):319-26. PubMed ID: 19337952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension.
    Gaddam KK; Pratt-Ubunama MN; Calhoun DA
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):353-9. PubMed ID: 16716096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary aldosteronism: renaissance of a syndrome.
    Young WF
    Clin Endocrinol (Oxf); 2007 May; 66(5):607-18. PubMed ID: 17492946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Normokalemic primary hyperaldosteronism].
    Vonend O; Rump LC
    Dtsch Med Wochenschr; 2006 Nov; 131(46 Spec No):H24-7. PubMed ID: 17109245
    [No Abstract]   [Full Text] [Related]  

  • 19. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
    Chrysostomou A; Pedagogos E; MacGregor L; Becker GJ
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aldosterone receptor antagonists].
    Muller O; Firsov D; Seydoux C
    Rev Med Suisse; 2007 May; 3(113):1401-4. PubMed ID: 17645055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.